---
schema_version: "secwatch.filing_event.v1"
accession: "0001005286-25-000009"
form_type: "8-K"
ticker: "LFCR"
cik: "0001005286"
company_name: "LIFECORE BIOMEDICAL, INC. DE"
filed_at: "2025-01-02T23:59:59+00:00"
generated_at: "2026-05-28T17:18:58.520134+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lifecore Q2 FY25 revenue up 8% to $32.6M; net loss $6.6M on non-cash items; adj EBITDA $6.5M

## Summary
- Revenue $32.6M (+8% YoY); CDMO segment drove $1.9M increase, partially offset by customer mix shifts.
- Net loss of $6.6M ($0.25 diluted loss) vs prior-year net income of $14.2M which included a $20.7M non-cash gain.
- Adjusted EBITDA $6.5M, up from $5.4M YoY, driven by higher gross profit from pricing and mix.
- Completed $24.3M equity private placement and amended BMO credit facility with lower rates and 3-year extension.
- Signed new CDMO project with Nirsum Labs; installed GMP-ready 5-head isolator filler, doubling capacity to ~$300M annual revenue potential.

## SEC filing metadata
- accession: 0001005286-25-000009
- form_type: 8-K
- ticker: LFCR
- cik: 0001005286
- company_name: LIFECORE BIOMEDICAL, INC. DE
- filed_at: 2025-01-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000009/0001005286-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000009/lndc-20250102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001005286-25-000009
- JSON: https://secwatch.observer/filing/0001005286-25-000009.json
- Plain text: https://secwatch.observer/filing/0001005286-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.